TWD 70.7
(-3.42%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 320.99 Million TWD | 91.56% |
2022 | 167.56 Million TWD | -6.34% |
2021 | 178.91 Million TWD | -25.55% |
2020 | 240.32 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 284.09 Million TWD | -11.49% |
2024 Q2 | 347.17 Million TWD | 22.2% |
2023 Q2 | 608.8 Million TWD | 273.49% |
2023 FY | 320.99 Million TWD | 91.56% |
2023 Q1 | 163 Million TWD | 0.0% |
2023 Q4 | 320.99 Million TWD | -11.2% |
2023 Q3 | 361.48 Million TWD | -40.62% |
2022 Q4 | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 64.731% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -13.611% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 45.593% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 90.471% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 91.152% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 95.173% |
Center Laboratories, Inc. | 6.78 Billion TWD | 95.27% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -99.31% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 64.022% |
InnoPharmax Inc. | 48.64 Million TWD | -559.814% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 32.119% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 58.088% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 47.969% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -14.281% |
UniPharma Co., Ltd. | 37.4 Million TWD | -758.247% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 68.385% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -321.865% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 14.144% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -545.588% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -195.161% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -140.217% |